Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProKidney ( (PROK) ) has shared an update.
On July 8, 2025, ProKidney Corp. announced statistically significant and clinically meaningful topline results from its Phase 2 REGEN-007 trial, which evaluated rilparencel in patients with CKD and diabetes. The study showed a robust improvement in kidney function for Group 1, with a 78% improvement in eGFR slope, and evidence of a dose response in Group 2. No serious adverse events related to rilparencel were observed. The results bolster confidence in the ongoing Phase 3 PROACT 1 study and support the use of eGFR slope as a surrogate endpoint for accelerated approval. ProKidney plans to submit the full results to the American Society of Nephrology 2025 Kidney Week.
The most recent analyst rating on (PROK) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The company is developing rilparencel, an autologous cellular therapy, to preserve kidney function in patients with advanced CKD and type 2 diabetes. ProKidney’s market focus includes patients with Stage 3b/4 CKD and diabetes, a significant population in the U.S. with unmet clinical needs.
Average Trading Volume: 1,137,111
Technical Sentiment Signal: Sell
Current Market Cap: $177.5M
Learn more about PROK stock on TipRanks’ Stock Analysis page.